[go: up one dir, main page]

EE03606B1 - Kristalliline [R-(R*,R*)]-2-(4-fluorofenüül)-beeta, delta-dihüdroksü-5-(1-metüületüül)-3-fenüül-4-[(fenüülamino)karbonüül]-1H-pürrool-1-hept aanhappehemikaltsiumsool (atorvastatiin) - Google Patents

Kristalliline [R-(R*,R*)]-2-(4-fluorofenüül)-beeta, delta-dihüdroksü-5-(1-metüületüül)-3-fenüül-4-[(fenüülamino)karbonüül]-1H-pürrool-1-hept aanhappehemikaltsiumsool (atorvastatiin)

Info

Publication number
EE03606B1
EE03606B1 EE9800015A EE9800015A EE03606B1 EE 03606 B1 EE03606 B1 EE 03606B1 EE 9800015 A EE9800015 A EE 9800015A EE 9800015 A EE9800015 A EE 9800015A EE 03606 B1 EE03606 B1 EE 03606B1
Authority
EE
Estonia
Prior art keywords
calcium
atorvastatin
phenylamino
methylethyl
fluorophenyl
Prior art date
Application number
EE9800015A
Other languages
English (en)
Estonian (et)
Other versions
EE9800015A (et
Inventor
Allen Jennings Rex
A. Briggs Christopher
A. Wade Robert
Harasawa Kikuko
Ichikawa Shigeru
Minohara Kazuo
Nakagawa Shinsuke
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21696090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE03606(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of EE9800015A publication Critical patent/EE9800015A/xx
Publication of EE03606B1 publication Critical patent/EE03606B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
EE9800015A 1995-07-17 1996-07-08 Kristalliline [R-(R*,R*)]-2-(4-fluorofenüül)-beeta, delta-dihüdroksü-5-(1-metüületüül)-3-fenüül-4-[(fenüülamino)karbonüül]-1H-pürrool-1-hept aanhappehemikaltsiumsool (atorvastatiin) EE03606B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US145295P 1995-07-17 1995-07-17
PCT/US1996/011368 WO1997003959A1 (fr) 1995-07-17 1996-07-08 Formes cristallines d'hemi-sel de calcium d'acide [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoique (atorvastatine)

Publications (2)

Publication Number Publication Date
EE9800015A EE9800015A (et) 1998-08-17
EE03606B1 true EE03606B1 (et) 2002-02-15

Family

ID=21696090

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800015A EE03606B1 (et) 1995-07-17 1996-07-08 Kristalliline [R-(R*,R*)]-2-(4-fluorofenüül)-beeta, delta-dihüdroksü-5-(1-metüületüül)-3-fenüül-4-[(fenüülamino)karbonüül]-1H-pürrool-1-hept aanhappehemikaltsiumsool (atorvastatiin)

Country Status (37)

Country Link
US (1) US5969156A (fr)
EP (2) EP0848705B1 (fr)
JP (4) JP3296564B2 (fr)
KR (2) KR100431038B1 (fr)
CN (1) CN1087288C (fr)
AR (2) AR003459A1 (fr)
AT (3) ATE284868T1 (fr)
AU (1) AU725424B2 (fr)
BG (1) BG63630B1 (fr)
BR (1) BR9609872A (fr)
CA (1) CA2220018C (fr)
CO (1) CO4700443A1 (fr)
CY (1) CY2358B1 (fr)
CZ (3) CZ294695B6 (fr)
DE (2) DE69616808T2 (fr)
DK (2) DK0848705T3 (fr)
EA (1) EA000474B1 (fr)
EE (1) EE03606B1 (fr)
ES (2) ES2167587T3 (fr)
GE (1) GEP20002029B (fr)
HR (1) HRP960339B1 (fr)
HU (1) HU223599B1 (fr)
IL (7) IL128864A (fr)
MX (1) MX9709099A (fr)
NO (1) NO309898B1 (fr)
NZ (1) NZ312907A (fr)
PE (1) PE1898A1 (fr)
PL (1) PL193479B1 (fr)
PT (2) PT1148049E (fr)
RO (1) RO120070B1 (fr)
SI (2) SI1148049T1 (fr)
SK (1) SK284202B6 (fr)
TW (1) TW486467B (fr)
UA (1) UA51661C2 (fr)
UY (2) UY24285A1 (fr)
WO (1) WO1997003959A1 (fr)
ZA (1) ZA966044B (fr)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
HRP960312B1 (en) 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
EP0848705B1 (fr) * 1995-07-17 2001-11-07 Warner-Lambert Company Formes cristallines d'hemi-sel de calcium d'acide r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl]-1h-pyrrole-1-heptanoique (atorvastatine)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
US6569461B1 (en) 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
IN191236B (fr) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
HUP0203257A3 (en) * 1999-11-17 2003-05-28 Teva Pharma Polymorphic forms of atorvastatin calcium, process for their preparations and pharmaceutical compositions containing them
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (sl) 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
AU776613B2 (en) * 1999-12-17 2004-09-16 Pfizer Science And Technology Ireland Limited A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt
CA2391357C (fr) * 1999-12-17 2009-01-06 Warner Lambert Research And Development Ireland Limited Procede pour produire de l'atorvastatine calcique cristallin
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US6258767B1 (en) * 2000-04-26 2001-07-10 Colgate-Palmolive Co. Spherical compacted unit dose softener
WO2001093860A1 (fr) 2000-06-09 2001-12-13 Lek Pharmaceuticals D.D. Composition stabilisee pharmaceutiquement efficace et preparation pharmaceutique comprenant cette composition
US6806290B2 (en) 2000-06-09 2004-10-19 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
WO2002041834A2 (fr) * 2000-11-03 2002-05-30 Teva Pharmaceutical Industries, Ltd. Atorvastatine hemicalcique forme vii
US6777552B2 (en) 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
RU2344127C2 (ru) * 2000-11-30 2009-01-20 Тева Фамэситикл Индастрис Лтд. Новые кристаллические структуры (полиморфные модификации) полукальциевой соли аторвастатина и способы получения этих и других полиморфных модификаций соли аторвастатина
CA2432096A1 (fr) * 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Procedes de preparation de lipopeptides purifies
US20060014674A1 (en) * 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
DE60137364D1 (de) 2000-12-27 2009-02-26 Teva Pharma Kristalline formen von atorvastatin
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
EP1728785A1 (fr) 2001-01-09 2006-12-06 Warner-Lambert Company LLC 7-[(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-heptanoic acid ester 3,5-dioxo-acetal
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
WO2002057229A1 (fr) * 2001-01-19 2002-07-25 Biocon India Limited FORME V CRISTALLINE DE SEL HEMICALCIQUE D'ACIDE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIQUE (ATORVASTATINE)
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
MXPA03010266A (es) * 2001-06-29 2004-03-10 Warner Lambert Co Formas cristalinas de la sal de calcio del acido [r-(r*, r*)]-2 -(4-fluorofenil)-¦, d-dihidroxi-5 -(1-metiletil)-3 -fenil-4- [(fenilamino) carbonil ]-1h- pirrol-1-heptanoico (2:1) (atorvastatin).
EP1406660B1 (fr) * 2001-07-19 2007-06-06 Pharmacia Corporation Combinaison d'un antagoniste de recepteur d'aldosterone et d'un inhibiteur de reducatse d'hmg coa
US7074818B2 (en) 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
HRP20040077A2 (en) * 2001-07-30 2004-06-30 Reddys Lab Ltd Dr Crystalline forms vi and vii of atorvastatin-calcium
US20030114497A1 (en) * 2001-07-31 2003-06-19 Laman Alani Pharmaceutical compositions of amlodipine and atorvastatin
CN100430405C (zh) * 2001-08-16 2008-11-05 特瓦制药工业有限公司 制备他汀类的钙盐形式的方法
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
US20060173064A1 (en) * 2001-08-24 2006-08-03 Lippa Arnold S (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
HU227124B1 (en) * 2001-09-14 2010-07-28 Egis Gyogyszergyar Nyilvanosan Polymorphs of 1-pyrrole derivative, intermediate for the preparation of atorvastatin
US20060020137A1 (en) * 2001-11-29 2006-01-26 Limor Tessler Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
CZ296967B6 (cs) 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
CA2475864A1 (fr) * 2002-02-15 2003-08-28 Teva Pharmaceutical Industries Ltd. Nouvelles formes cristallines d'hemi-calcium d'atorvastatine
CA2475123A1 (fr) * 2002-02-19 2003-08-28 Teva Pharmaceutical Industries Ltd. Processus destines a la desolvation des solvates de demi-calcium d'atorvastatine et demi-calcium d'atorvastatine sensiblement exempt de solvant organique
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
HUP0201083A2 (hu) * 2002-03-28 2004-06-28 Richter Gedeon Vegyészeti Gyár Rt. Új atorvastatinsók és az azokat tartalmazó gyógyszerkészítmények
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
ATE368661T1 (de) * 2002-08-06 2007-08-15 Warner Lambert Co Verfahren zur herstellung von 5-(4-fluorphenyl)-1- 2-((2r,4r)-4-hydroxy-6-oxo etrahydropyran-2- yl)ethylö-2-isopropyl-4-phenyl-1h-pyrrol-3- carbonsäurephenylamid
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
EP1562583A1 (fr) * 2002-09-03 2005-08-17 Morepen Laboratories Ltd. Forme vi de calcium d'atorvastatine ou hydrates de cette derniere
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
HRP20020885B1 (en) * 2002-11-11 2007-05-31 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. SUBSTITUTED 9a-N-{N'-[4-(SULFONYL)PHENYLCARBAMOYL]}DERIVATIVES 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHROMYCIN A AND 5-O-DESOZAMINYL-9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHRONOLIDE A
EP1424324A1 (fr) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Forme cristalline F de calcium d'atorvastatine
WO2004050618A2 (fr) * 2002-11-28 2004-06-17 Teva Pharmaceutical Industries Ltd. Forme cristalline
AU2004222436A1 (en) * 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate
EP1615883A1 (fr) * 2003-04-14 2006-01-18 Warner-Lambert Company Procede de preparation de phenylamide d'acide carboxylique 5-(4-fluorophenyl)-1- 2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3
TWI494102B (zh) * 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
US20040248972A1 (en) * 2003-05-16 2004-12-09 Ambit Biosciences Corporation Compounds and uses thereof
JP2007516227A (ja) * 2003-05-16 2007-06-21 アンビット バイオサイエンシス コーポレーション ピロール化合物およびその使用
US20040242670A1 (en) * 2003-06-02 2004-12-02 Sonny Sebastian Process for preparation of amorphous atorvastatin calcium
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
CN1852894A (zh) * 2003-09-17 2006-10-25 沃尼尔·朗伯有限责任公司 [R－(R*, R*)]－2－(4－氟苯基) －β,δ－二羟基－5－(1－甲基乙基) －3－苯基－4－[(苯基氨基)羰基] －1 H－吡咯－1－庚酸的结晶形式
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
JP2007513144A (ja) * 2003-12-05 2007-05-24 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ＨＭＧ−ＣｏＡレダクターゼ阻害剤としてのＮ−アルキルピロール
EP1709008A1 (fr) * 2004-01-19 2006-10-11 Ranbaxy Laboratories Limited Sels des inhibiteurs de hmg-coa reductase et leur utilisation
CA2456430A1 (fr) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Procede ameliore pour la preparation d'atorvastatine calcique amorphe
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
EP1761489A1 (fr) * 2004-03-17 2007-03-14 Ranbaxy Laboratories Limited Forme cristalline d'hemi-calcium d'atorvastatine
PL1727795T3 (pl) 2004-03-17 2012-06-29 Ranbaxy Laboratories Ltd Sposób wytwarzania soli wapniowej atorwastatyny w formie bezpostaciowej
BRPI0509926A (pt) * 2004-04-16 2007-09-18 Warner Lambert Co imidazóis
CN1960972A (zh) * 2004-04-16 2007-05-09 辉瑞产品公司 用于形成无定形阿托伐它汀钙的方法
EP2540704B1 (fr) 2004-05-05 2019-07-03 Pfizer Products Inc. Formes de sel de bénéthamine avec l'atorvastatine
CA2833770A1 (fr) * 2004-07-16 2006-01-26 Lek Pharmaceuticals D.D Produits de degradation oxydante du calcium d'atorvastatine
CA2754932C (fr) 2004-07-20 2014-04-01 Warner-Lambert Company Llc Nouvelles formes de [r-(r*,r*)]-2-(4-fluorophenyl).beta.,.delta.-dihydroxy-5-(isopropyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoatede calcium (2:1)
ES2262459T1 (es) * 2004-07-22 2006-12-01 Teva Pharmaceutical Industries Ltd Nuevas formas cristalinas de atorvastatina semicalcica y procedimientos para su preparacion.
US20070043100A1 (en) * 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
CA2578722C (fr) 2004-08-27 2010-02-02 Biocon Limited Processus pour calcium d'atorvastatine amorphe
DE202005020841U1 (de) * 2004-09-28 2006-08-31 Teva Pharmaceutical Industries Ltd. Formen von Atorvastatin-Calcium, die im wesentlichen frei von Verunreinigungen sind
CN101039906A (zh) 2004-10-18 2007-09-19 特瓦制药工业有限公司 通过将盐溶解于有机溶剂并除去该溶剂来制备无定形阿托伐他汀半钙的方法，所述有机溶剂为醇和酮和 /或酯的混合物
WO2006046109A1 (fr) 2004-10-28 2006-05-04 Warner-Lambert Company Llc Procede de formation d'atorvastatine amorphe
WO2006048888A1 (fr) * 2004-11-01 2006-05-11 Jubilant Organosys Limited Nouveau procede de preparation du sel de calcium d’atorvastatine amorphe
US20060100263A1 (en) * 2004-11-05 2006-05-11 Anthony Basile Antipyretic compositions and methods
WO2006048894A1 (fr) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Nouvelles formes cristallines de calcium d'atorvastatine et procedes de fabrication
AU2005305460B2 (en) * 2004-11-22 2011-04-21 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
MX2007005137A (es) * 2004-11-23 2007-06-22 Warner Lambert Co Derivados del acido 7-(2h-pyrazol-3-il)-3, 5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de lipidemia.
US20090088465A1 (en) * 2004-12-02 2009-04-02 Stephen Craig Dyar Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same
WO2006059210A2 (fr) * 2004-12-03 2006-06-08 Warner-Lambert Company Llc Pyrrols bicycliques fusionnes comme inhibiteurs de la reductase as hmg-coa
EP1671947A1 (fr) * 2004-12-20 2006-06-21 Ratiopharm GmbH Procédé de préparation de dérivés de pyrrol et intermédiaires
SK288276B6 (sk) * 2005-04-08 2015-06-02 Egis Gyógyszergyár, Nyilvánosan Működő Részvénytársaság Spôsob prípravy kryštalickej polymorfnej formy hemivápenatej soli atorvastatínu
EP1919466B9 (fr) 2005-07-11 2012-05-16 Cortria Corporation Formulations pour le traitement des anormalites liees aux lipoproteines comprenant une statine et un derive de la methylnicotinamide
WO2007016155A2 (fr) 2005-07-27 2007-02-08 Dov Pharmaceutical, Inc. Nouveaux 1-aryl-3-azabicyclo[3.1.0]hexanes : synthèse et emploi dans le traitement des troubles neuropsychiatriques
US20070032665A1 (en) * 2005-08-04 2007-02-08 Srinivasulu Gudipati Preparation of atorvastatin calcium form i
CN101268047B (zh) 2005-08-15 2012-11-07 箭锋国际有限公司 结晶和无定形阿托伐他汀钠
CA2619486C (fr) 2005-08-15 2015-05-12 Arrow International Limited Atorvastatine de sodium amorphe cristalline
EP1919393A2 (fr) * 2005-09-01 2008-05-14 Prescient Medical, Inc. Medicaments enrobant un dispositif destine a traiter une plaque vulnerable
CA2547216A1 (fr) 2005-09-21 2007-03-21 Renuka D. Reddy Procede de recuit de l'atorvastatine amorphe
DK1957452T3 (da) 2005-11-21 2010-07-26 Warner Lambert Co Nye former af [R-(R*,R*)]-2-(4-fluorphenyl)-B,B-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyre- magnesium
MX2007014329A (es) * 2005-12-13 2008-03-19 Teva Pharma Forma cristalina de hemi-calcio de atorvastatina y procesos para la preparacion de ella.
EP1810667A1 (fr) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Composition pharmaceutique contenant de l'atorvastatin amorphé
US20090240064A1 (en) * 2006-02-22 2009-09-24 Venkata Panakala Rao Gogulapati Crystalline form of atorvastatin hemi-calcium
US20080045725A1 (en) * 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
US20070265456A1 (en) * 2006-05-09 2007-11-15 Judith Aronhime Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
ES2376396T3 (es) 2006-06-26 2012-03-13 Amgen Inc. Método para tratar aterosclerosis.
CA2655881A1 (fr) * 2006-06-28 2008-01-03 Teva Pharmaceutical Industries Ltd. Formes cristallines d'atorvastatine
CN101528917B (zh) 2006-10-02 2015-07-29 科德克希思公司 用于制备立体异构纯的他汀类及其合成中间体的组合物和方法
US8138377B2 (en) * 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US20080269348A1 (en) * 2006-11-07 2008-10-30 Phil Skolnick Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use
US7834195B2 (en) 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
KR100878140B1 (ko) * 2007-01-29 2009-01-12 한미약품 주식회사 아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물
PT103661B (pt) * 2007-02-23 2010-09-07 Hovione Farmaciencia S A Processo de preparação de minociclina base cristalina
KR101012917B1 (ko) * 2007-03-02 2011-02-08 동아제약주식회사 피롤 헵탄산 화합물의 신규한 결정형
US20080249141A1 (en) * 2007-04-06 2008-10-09 Palepu Nageswara R Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
US20080248115A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent
WO2008124122A1 (fr) * 2007-04-09 2008-10-16 Scidose, Llc Combinaisons de statines, d'agent anti-obésité et de glitazones
US20090069374A1 (en) * 2007-06-06 2009-03-12 Phil Skolnick Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
WO2009013633A2 (fr) * 2007-07-20 2009-01-29 Actavis Group Ptc Ehf Coprécipités amorphes de sels pharmaceutiquement acceptables d'atorvastatine
SI2489731T1 (sl) 2007-07-26 2014-12-31 Amgen Inc. Patent Operations, M/S 28-2-C Modificirani encimi lecitin-holesterol aciltransferaze
NZ583607A (en) 2007-09-21 2012-06-29 Epiphany Biosciences Inc Valomaciclovir polymorphs
KR100813666B1 (ko) 2007-10-23 2008-03-14 (주)에이에스텍 콜레스테롤 합성 저해제로서 아토르바스타틴의 프로드럭
DE102007052071A1 (de) 2007-10-30 2009-05-07 Stada Arzneimittel Ag Stabilisiertes Atorvastatin
US20090124817A1 (en) * 2007-11-09 2009-05-14 The Industry & Academic Cooperation In Chungnam National University Process for Preparing Amorphous Atorvastatin Calcium Nanoparticles
US20110064816A1 (en) * 2008-05-13 2011-03-17 Dr. Reddy's Laboratories Ltd. Atorvastatin compositions
US8115015B2 (en) * 2009-01-26 2012-02-14 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
CA2757722C (fr) 2009-04-01 2018-05-22 Matrix Laboratories Ltd. Procede enzymatique pour la preparation de la (s)-5-(4-fluorophenyl)-5-hydroxy-1-morpholin-4-yl-pentan-1-one, un intermediaire de l'ezetimibe et la conversion ulterieure en ezetim ibe
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
AU2011308911B2 (en) * 2010-09-30 2014-10-02 Wisconsin Alumni Research Foundation (20R,25S)-2-methylene-19,26-dinor-1alpha, 25-dihydroxyvitamin D3 in crystalline form
HU230737B1 (hu) 2010-11-16 2018-01-29 EGIS Gyógyszergyár Nyrt Eljárás rosuvastatin só előállítására
US20120165386A1 (en) * 2010-12-27 2012-06-28 Ranbaxy Laboratories Limited Stable oral pharmaceutial composition of atorvastatin
US9050342B2 (en) 2011-03-29 2015-06-09 Pfizer Inc. Beneficial effects of combination therapy on cholesterol
MX2013015272A (es) * 2011-07-01 2014-04-14 Dsm Sinochem Pharm Nl Bv Cristales micronizados.
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
WO2013072770A2 (fr) 2011-11-15 2013-05-23 Dr. Reddy's Laboratories Ltd. Formulations pharmaceutiques comprenant de l'atorvastatine et du glimépiride
AU2012347540A1 (en) 2011-12-08 2014-06-26 Amgen Inc. Agonistic human LCAT antigen binding proteins and their use in therapy
JP2015515498A (ja) * 2012-04-30 2015-05-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規製剤
CN103483238B (zh) * 2013-08-20 2014-12-31 蚌埠丰原医药科技发展有限公司 阿托伐他汀钙三水合物的制备方法
CA2958898A1 (fr) 2014-09-15 2016-03-24 The Board Of Trustees Of The Leland Stanford Junior University Ciblage d'une maladie anevrismale par des voies de modulation de la phagocytose
ES2838925T3 (es) 2015-02-27 2021-07-02 Univ Leland Stanford Junior Terapia de combinación para el tratamiento de la ateroesclerosis
CN104945300B (zh) * 2015-06-17 2017-05-10 北京嘉林药业股份有限公司 一种ⅰ型阿托伐他汀钙的纯化方法
EP3184103A1 (fr) 2015-12-21 2017-06-28 Hexal AG Composition pharmaceutique comprenant de l'atorvastatine ou un sel de celui-ci
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
KR101723783B1 (ko) * 2017-02-24 2017-04-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
JP7370252B2 (ja) 2017-05-30 2023-10-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 神経炎症性疾患の治療
EP3501502A1 (fr) 2017-12-20 2019-06-26 Midas Pharma GmbH Compositions pharmaceutiques dosées fixes comprenant de l'amlodipine, du ramipril et de l'atorvastatine
CN108558726A (zh) * 2018-03-14 2018-09-21 湖北广济药业股份有限公司 一种高纯度阿托伐他汀钙的制备方法
CN110776451B (zh) * 2020-01-02 2020-05-22 湖南迪诺制药股份有限公司 一种i晶型阿托伐他汀钙的制备方法
KR20210001641U (ko) 2020-01-08 2021-07-16 주식회사 다마가산업 최소구성의 초저가 콘크리트 타설 레벨표시구
EP4052695A1 (fr) 2021-03-05 2022-09-07 Midas Pharma GmbH Compositions pharmaceutiques orales stables à libération immédiate à dose fixe comprenant de l'amlodipine, de l'atorvastatine et du candésartan cilexétil
WO2025147589A1 (fr) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions et méthodes de traitement de maladies et de troubles de la rétine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456753A (en) 1983-02-07 1984-06-26 Pfizer Inc. Process for the manufacture of highly crystalline sodium cefoperazone
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5316765A (en) * 1989-09-07 1994-05-31 Karl Folkers Foundation For Biomedical And Clinical Research Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
JP3528186B2 (ja) 1991-06-24 2004-05-17 日産化学工業株式会社 光学活性キノリンメバロン酸のジアステレオマー塩
DE4235133A1 (de) 1992-10-19 1994-04-21 Bayer Ag Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid
DE69324504T2 (de) * 1993-01-19 1999-08-26 Warner-Lambert Co. Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
JP3623531B2 (ja) 1993-06-07 2005-02-23 ビーエーエスエフ アクチェンゲゼルシャフト 結晶質ｌ−アスコルビン酸−２−燐酸エステルマグネシウム塩の製造法
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
EP0848705B1 (fr) * 1995-07-17 2001-11-07 Warner-Lambert Company Formes cristallines d'hemi-sel de calcium d'acide r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl]-1h-pyrrole-1-heptanoique (atorvastatine)
AU776613B2 (en) 1999-12-17 2004-09-16 Pfizer Science And Technology Ireland Limited A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt
CA2391357C (fr) 1999-12-17 2009-01-06 Warner Lambert Research And Development Ireland Limited Procede pour produire de l'atorvastatine calcique cristallin
MXPA03010266A (es) 2001-06-29 2004-03-10 Warner Lambert Co Formas cristalinas de la sal de calcio del acido [r-(r*, r*)]-2 -(4-fluorofenil)-¦, d-dihidroxi-5 -(1-metiletil)-3 -fenil-4- [(fenilamino) carbonil ]-1h- pirrol-1-heptanoico (2:1) (atorvastatin).

Also Published As

Publication number Publication date
DE69616808D1 (en) 2001-12-13
ES2167587T3 (es) 2002-05-16
UA51661C2 (uk) 2002-12-16
AR003458A1 (es) 1998-08-05
EA000474B1 (ru) 1999-08-26
EP0848705A1 (fr) 1998-06-24
HK1018052A1 (en) 1999-12-10
CO4700443A1 (es) 1998-12-29
CZ294740B6 (cs) 2005-03-16
DE69634054D1 (de) 2005-01-20
PT848705E (pt) 2002-02-28
JP4790194B2 (ja) 2011-10-12
KR100389518B1 (ko) 2003-11-15
IL128862A0 (en) 2000-01-31
EP0848705B1 (fr) 2001-11-07
UY24285A1 (es) 1997-01-17
EP1148049B1 (fr) 2004-12-15
AT8453U1 (de) 2006-08-15
ATE208375T1 (de) 2001-11-15
JP2014051533A (ja) 2014-03-20
AU6484296A (en) 1997-02-18
CZ294695B6 (cs) 2005-02-16
IL128865A (en) 2006-04-10
IL128864A0 (en) 2000-01-31
HUP9900678A3 (en) 2000-04-28
JP3296564B2 (ja) 2002-07-02
PT1148049E (pt) 2005-02-28
BG63630B1 (bg) 2002-07-31
NO980207L (no) 1998-01-16
CN1190955A (zh) 1998-08-19
ATE284868T1 (de) 2005-01-15
UY24985A1 (es) 2001-03-16
NO980207D0 (no) 1998-01-16
JP2003073353A (ja) 2003-03-12
AU725424B2 (en) 2000-10-12
CY2358B1 (en) 2004-06-04
IL122118A0 (en) 1998-04-05
IL128862A (en) 2007-12-03
HUP9900678A2 (hu) 1999-07-28
IL203847A0 (en) 2011-08-01
HU223599B1 (hu) 2004-10-28
IL128864A (en) 2007-10-31
DK0848705T3 (da) 2002-02-04
CZ12198A3 (cs) 1998-10-14
CZ294108B6 (cs) 2004-10-13
HRP960339A2 (en) 1998-04-30
KR100431038B1 (ko) 2004-05-12
ES2233526T3 (es) 2005-06-16
JP2011195592A (ja) 2011-10-06
KR19990029043A (ko) 1999-04-15
RO120070B1 (ro) 2005-08-30
IL128865A0 (en) 2000-01-31
BG102187A (en) 1998-10-30
SK6298A3 (en) 1998-10-07
NO309898B1 (no) 2001-04-17
CA2220018A1 (fr) 1997-02-06
DE69616808T2 (de) 2002-05-29
KR20030097628A (ko) 2003-12-31
NZ312907A (en) 2000-12-22
JPH11509230A (ja) 1999-08-17
ZA966044B (en) 1997-02-03
CN1087288C (zh) 2002-07-10
PL324496A1 (en) 1998-05-25
PL193479B1 (pl) 2007-02-28
EA199800130A1 (ru) 1998-08-27
SI0848705T1 (en) 2002-04-30
MX9709099A (es) 1998-02-28
TW486467B (en) 2002-05-11
WO1997003959A1 (fr) 1997-02-06
SI1148049T1 (en) 2005-02-28
DE69634054T2 (de) 2005-12-08
HRP960339B1 (en) 2002-06-30
US5969156A (en) 1999-10-19
CA2220018C (fr) 2001-04-17
GEP20002029B (en) 2000-04-10
PE1898A1 (es) 1998-03-04
IL122118A (en) 1999-07-14
SK284202B6 (sk) 2004-10-05
DK1148049T3 (da) 2005-03-29
AR003459A1 (es) 1998-08-05
IL177377A0 (en) 2006-12-10
IL177376A0 (en) 2006-12-10
EP1148049A1 (fr) 2001-10-24
BR9609872A (pt) 1999-03-23
EE9800015A (et) 1998-08-17

Similar Documents

Publication Publication Date Title
EE03606B1 (et) Kristalliline [R-(R*,R*)]-2-(4-fluorofenüül)-beeta, delta-dihüdroksü-5-(1-metüületüül)-3-fenüül-4-[(fenüülamino)karbonüül]-1H-pürrool-1-hept aanhappehemikaltsiumsool (atorvastatiin)
DK0839132T5 (da) Fremgangsmåde til fremstilling af amorft [R-(R*,R*)]-2-(4-fluorphenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyrecalciumsalt (2:1)
IL158790A0 (en) Crystalline forms of [r-(*,r*)]-2-(4-fluorophenyl) -beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
ATE207465T1 (de) Kristalline form iii des hemi calcium salzes von (r-(r*,r*))-2-(4-fluorphenyl)-beta-delta- dihydroxy-5-(1-methylethyl)-3-phenyl-4- ((phenylamino)carbonyl)-1h-pyrrol-1-heptansäure (atorvastatin)
EP1472220A4 (fr) Sel de calcium cristallin (2:1) de l'acide (r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-heptanoique
IL173651A0 (en) Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
DE69616358D1 (de) Kristalline form iii des hemi calcium salzes von [r-(r*,r*)]-2-(4-fluorphenyl)-beta-delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrol-1-heptansäure (atorvastatin)
NZ507836A (en) Crystalline [r*(r* ,r*)]-2-(4-flurophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
HK1056556A (en) HYDROLYSIS OF [R(R*,R*)]-2-(4-FLUOROPHENYL)-β, δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE
AU2001234058A1 (en) Form v crystalline (r-(r*,r*))-2-(4-fluorophenyl)-ss,$g(d)-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1- heptanoic acid hemi calcium salt. (atorvastatin)

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

LD4A Amendment in the specification
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

HC1A Change of owner name